The centralized procurement policy has significantly reduced drug prices through an open and transparent bidding mechanism, and enhanced the cost-effectiveness of drugs. As an important component of the centralized procurement policy, China has been encouraging the substitution of generic drugs for originator drugs in recent years to lower medical costs and has increased investment in the cost of generic drugs. However, the promotion of generic drugs still needs to overcome multiple challenges such as doctors' trust and patients' acceptance. Overall, the centralized procurement policy has achieved remarkable results in reducing drug costs, optimizing supply security, and promoting the development of generic drugs. However, it is also necessary to ensure the sustainability of the policy and the diversity of drug treatments. In the future, the deepening development of the centralized procurement policy will further promote the high-quality development of the generic drug industry. This article reviews different drug procurement models at home and abroad, the development process of the domestic centralized procurement policy, the impact of the centralized procurement policy on drug use and the challenges it faces, as well as the research on generic drug products under the centralized procurement policy, and discusses the future development direction of generic drugs.

1.王彪, 张天天, 唐啸宇, 等. 国家组织药品带量采购政策的降价持续性研究[J]. 中国卫生政策研究, 2023, 16(4): 32-36. [Wang B, Zhang TT, Tang XY, et al. A study on the sustainability of price reductions in national volume-based drug procurement policy[J]. Chinese Journal of Health Policy, 2023, 16(4): 32-36.] DOI: 10.3969/j.issn.1674-2982.2023.04.005.

2.罗学广, 林意. “4+7”集中采购国家集采药品政策对基层医院的影响及建议[J]. 世界最新医学信息文摘, 2021, 21(101): 540-542. [Luo XG, Lin Y. The Impact of the "4+7" centralized procurement national drug procurement policy on primary hospitals and suggestions[J]. World Latest Medicine Information, 2021, 21(101): 540-542.] DOI: 10.3969/j.issn.1671-3141.2021.101.261.

3.刘玉娟. 英国和美国医疗保险制度比较与借鉴研究[J]. 现代商贸工业, 2010, 22(22): 110-111. [Liu YJ. Comparative study and reference of medical insurance systems in the UK and the US[J]. Modern Business Trade Industry, 2010, 22(22): 110-111.] DOI: 10.3969/j.issn.1672-3198.2010.22.062.

4.张婧, 李高洁, 蒋茜, 等. 美国药品成本管理策略对我国医疗机构药品费用控制启示[J]. 中国医院药学杂志, 2020, 40(12): 1303-1306. [Zhang J, Li GJ, Jiang Q, et al. Enlightenment of ASHP strategies on medication cost management for medical institutions in China[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(12): 1303-1306.] DOI: 10.13286/j.1001-5213.2020.12.05.

5.陈童, 蒋蓉, 邵蓉. 加拿大药品返利协议研究及对我国的启示[J]. 中国卫生政策研究, 2021, 14(4): 68-73. [Chen  T, Jiang R, Shao R. Research on the canadian pharmaceutical rebate agreements and its enlightenment to China[J]. Chinese Journal of Health Policy, 2021, 14(4): 68-73.] DOI: 10.3969/j.issn.1674-2982.2021.04.010.

6.孙致宣, 公令臣, 那昕, 等. 我国药品集中采购政策发展及对药品生产企业影响分析[J]. 中国医药工业杂志, 2024, 55(1): 143-148. [Sun ZX, Gong LC, Na X, et al. Analysis of the development of chinese national centralized drug procurement policy and its impact on drug manufacturers[J]. Chinese Journal of Pharmaceuticals, 2024, 55(1): 143-148.] DOI: 10.16522/j.cnki.cjph.2024.01.020.

7.张焕, 徐诺, 徐敢, 等. 药品可及性视角下415种过评仿制药与基药、医保、集采目录的联动情况分析[J]. 中国药房, 2022, 33(6): 661-665, 705. [Zhang H, Xu N, Xu G, et al. Analysis on the linkage of 415 generic medicines passing consistency evaluation and essential medicine list, medical insurance list and centralized procurement list from the perspective of medicine accessibility[J]. China Pharmacy, 2022, 33(6): 661-665, 705.] DOI: 10.6039/j.issn.1001-0408.2022.06.03.

8.孙文俊, 赵子寅, 成哲玉, 等. 药品集中采购政策对药品价格和使用影响的系统综述[J]. 中国卫生政策研究, 2023, 16(2): 52-58. [Sun WJ, Zhao ZY, Cheng ZY, et al. A systematic review on the impact of the volume-based procurement policy on prices and dosages of drugs[J]. Chinese Journal of Health Policy, 2023, 16(2): 52-58.] DOI: 10.3969/j.issn.1674-2982.2023.02.008.

9.刘苏苏, 茅宁莹. 集中带量采购政策对药品供应保障的影响 [J]. 中国药事, 2021, 35(4): 380-385. [Liu SS, Mao NY. Impact of centralized volumetric procurement policy on drug supply assurance[J]. Chinese Pharmaceutical Affairs, 2021, 35(4): 380-385.] DOI: 10.16153/j.1002-7777.2021.04.003.

10.周德雨, 蒯丽萍, 徐冬艳, 等. 国家集中带量采购药品的短缺情况分析与对策建议[J]. 中国药房, 2023, 34(7): 769-773. [Zhou DY, Kuai LP, Xu DY, et al. Analysis of the shortage of drugs in national centralized volume-based procurement and countermeasures and suggestions[J]. China Pharmacy, 2023, 34(7): 769-773.] DOI: 10.6039/j.issn.1001-0408.2023.07.01.

11.尹璇, 黄睿健, 伍俊妍, 等. 药品临床综合评价项目真实世界研究质量控制规范（2024版）[J]. 健康发展与政策研究, 2024, 27(5): 432-436. [Yin X Huang RJ, Wu JY, et al. Guidelines for quality control in real-world studies of drug clinical comprehensive evaluation projects (version 2024)[J]. Health Development and Policy Research, 2024, 27(5): 432-436.] DOI: 10.12458/HDPR.202408073.

12.徐源, 陈珉惺, 何江江, 等. 国家药品集中带量采购中标药品生产供应状况与保障建议[J]. 中国卫生经济, 2022, 41(7): 65-67. [Xu Y, Chen MX, He JJ, et al. Supply status of bid-winning drugs in national volume-based procurement and supporting suggestions[J]. Chinese Health Economics, 2022, 41(7): 65-67.] DOI: 10.6039/j.issn.1001-0408.2023.08.02.

13.邵靖, 路云, 常峰. 药品集中带量采购的应急管理机制研究 [J]. 中国药房, 2023, 34(8): 902-906. [Shao J, Lu Y, Chang  F. Study on emergency management mechanism of drug volume-based procurement[J]. China Pharmacy, 2023, 34(8): 902-906.] DOI: 10.6039/j.issn.1001-0408.2023.08.02.

14.马椿乔, 许惠溢, 徐峰, 等. 国家药品集中采购中选药品超量采购的帕累托图分析[J]. 海峡药学, 2022, 34(5): 84-88. [Ma CQ, Xu HY, Xu F, et al. Pareto chart analysis on centralized procurement of drugs in excess of procurement[J]. Strait Pharmaceutical Journal, 2022, 34(5): 84-88.] DOI: 10.3969/j.issn.1006-3765.2022.05.025.

15.张秋玉, 禄晓龙, 王芸, 等. 药品集中带量采购政策对我国医药制造业上市企业创新绩效的影响[J]. 医学与社会, 2022, 35(12): 17-23. [Zhang QY, Lu XL, Wang Y, et al. Effects of centralized volume-based procurement policy of drugs on innovation performance of listed pharmaceutical manufacturing enterprises in China[J]. Medicine and Society, 2022, 35(12): 17-23.] DOI: 10.13723/j.yxysh.2022.12.004.

16.唐运舒, 叶徽, 焦建玲, 等. 药品集采、以量换价与药企创新: 如何实现医药减负与药企创新发展的双赢?[J]. 中国软科学, 2023, (12): 123-133. [Tang YS, Ye H, Jiao JL, et al. Centralized drug procurement,volume-for-price,and pharmaceutical enterprise innovation: how to achieve a win-win for pharmaceutical burden reduction and innovative development of pharmaceutical enterprises?[J]. China Soft Science, 2023, (12): 123-133.] DOI: 10.3969/j.issn.1002-9753.2023.12.012.

17.蔡显军, 卞宇轩, 陈怡锋. 药品集采与企业创新投入[J]. 科学决策, 2023, (12): 102-118. [Cai XJ, Bian YX, Chen YF. Does volume-based drug procurement policy increase firms'innovation input?Evidence from listed biopharmaceutical enterprises[J]. Scientific Decision-Making, 2023, (12): 102-118.] DOI: 10.3773/j.issn.1006-4885.2023.12.102.

18.何锐, 葛靖, 何梦娇, 等. 博弈论视角下药品带量采购降价的影响因素分析[J]. 中国药房, 2020, 31(9): 1025-1029. [He R, Ge J, He MJ, et al. Analysis of influential factors for price reduction of drug quantity purchasing in perspective of gaming theory[J]. China Pharmacy, 2020, 31(9): 1025-1029.] DOI: 10.6039/j.issn.1001-0408.2020.09.01.

19.张倩, 李莲, 王琳, 等. "4+7"集采新政下医院药学部门药品的供应保障研究[J]. 临床合理用药杂志, 2022, 15(19): 163-165. [Zhang Q, Li L, Wang L, et al. Research on the supply and assurance of drugs in hospital pharmacy departments under the "4+7" centralized procurement policy[J]. Chinese Journal of Clinical Rational Drug Use, 2022, 15(19): 163-165.] DOI: 10.15887/j.cnki.13-1389/r.2022.19.051.

20.王芳旭, 陶立波. 生物药集采的特点、难点与政策进展[J]. 中国医疗保险, 2022, (4): 18-21. [Wang FX, Tao LB. Features, difficulties and policies of centralized biological drugs procurement in China[J]. China Health Insurance, 2022, (4): 18-21.] DOI: 10.19546/j.issn.1674-3830.2022.4.003.

21.刘敬峰, 左臣伟, 史扬帆, 等. 域外国家窄治疗指数药品的仿制药替代政策及其对我国的启示[J]. 中国药科大学学报, 2024, 55(4): 565-572. [Liu JF, Zuo CW, Shi YF, et al. Foreign generic drug substitution policies for narrow therapeutic index drugs and their implications for China[J]. Journal of China Pharmaceutical University, 2024, 55(4): 565-572.] DOI: 10.11665/j.issn.1000-5048.2023092301.

22.向金莲. 开展仿制药质量一致性评价的现状和意义[J]. 中国药物经济学, 2017, 12(7): 17-18, 34. [Xiang JL. The current situation and significance of the quality consistency evaluation of generic drugs[J]. China Journal of Pharmaceutical Economics, 2017, 12(7): 17-18, 34.] DOI: 10.12010/j.issn.1673-5846. 2017.07.004.

23.唐湘燕, 曹永芳, 何辉. "十四五"时期药品安全监管相关政策分析与比较[J]. 中国新药杂志, 2024, 33(7): 644-650. [Tang  XY, Cao YF, He H. Policy analysis and comparison related to drug safety supervision during the "14th Five-Year Plan" period[J]. Chinese Journal of New Drugs, 2024, 33(7): 644-650.] DOI: 10.3969/j.issn.1003-3734.2024.07.003.

24.王越, 文小桐, 段凤然, 等. 集采政策对制药企业在公立医疗机构药品销售的影响[J]. 中国医疗保险, 2023, (9): 106-112. [Wang Y, Wen XT, Duan FR, et al. Impact of national centralized drug procurement on pharmaceutical companies' drug sales in public medical institutions[J]. China Health Insurance, 2023, (9): 106-112.] DOI: 10.19546/j.issn.1674-3830.2023.9.014.

25.陆艺. 基于经济学原理的药品带量采购政策实施效果研究 [J]. 卫生软科学, 2024, 38(3): 75-78. [Lu Y. Research on the implementation effect of centralized volume-based drug purchase policy based on economic principles[J]. Soft Science of Health, 2024, 38(3): 75-78.] DOI: 10.3969/j.issn.1003-2800.2024.03.016.

26.李玲玲, 都丽萍, 张钰宣, 等. 仿制药与原研药间可互换性探讨[J]. 中国药学杂志, 2015, 50(2): 178-181. [Li LL, Du LP, Zhang YX, et al. Inter-changeability between generic medicines and brand-name medicines[J]. Chinese Pharmaceutical Journal, 2015, 50(2): 178-181.] DOI: 10.11669/cpj.2015.02.020.

27.李栋, 周誉. 依巴斯汀片生物等效性研究的一般设计要求及相关考虑[J]. 中国临床药理学杂志, 2022, 38(4): 365-368. [Li D, Zhou Y. General design requirements and relevant considerations on bioequivalence study of ebastine tablets[J]. The Chinese Journal of Clinical Pharmacology, 2022, 38(4): 365-368.] DOI: 10.13699/j.cnki.1001-6821.2022.04.017.

28.Jain KK. Investigation and management of loss of efficacy of anantiepileptic medication using carbamazepine as an example[J]. J Royal Soci Med,1993, 86(3): 133-136. DOI: 10.1177/014107689308600305.

29.陈美灵, 王庆利, 光红梅, 等. 药物制剂安全性评价及常见问题分析[J]. 中国临床药理学杂志, 2024, 40(1): 139-143. [Chen  ML, Wang QL, Guang HM, et al. Evaluation of drug local tolerance testing and analysis of common problems[J]. The Chinese Journal of Clinical Pharmacology, 2024, 40(1): 139-143.] DOI: 10.13699/j.cnki.1001-6821.2024.01.029.

30.罗巧, 董宪喆, 王之舟, 等. 二甲双胍带量采购中选仿制药疗效与安全性评价的真实世界研究[J]. 实用药物与临床, 2023, 26(5): 427-432. [Luo Q, Dong XZ Wang ZZ, et al. A real-world study on the efficacy and safety evaluation of metformin selected ge-neric drugs in volume-based procurement[J]. Practical Pharmacy and Clinical Remedies, 2023, 26(5): 427-432.] DOI: 10.14053/j.cnki.ppcr.202305008.

31.李桂丹, 何心. 原研与国产仿制左氧氟沙星注射液说明书的对比分析[J]. 中国药房, 2016, 27(25): 3598-3600. [Li GD, He X. Comparative analysis of the instructions of original and domestic generic levofloxacin injections[J]. China Pharmacy, 2016, 27(25): 3598-3600.] DOI: 10.6039/j.issn.1001-0408.2016.25.43.

32.赵洁, 李巍, 王皋俊. 价值医疗视角下国家药品集中带量采购在某公立医院的实施效果评价[J]. 中国药房, 2021, 32(19): 2410-2414. [Zhao J, Li W, Wang GJ. Effect evaluation of national drug centralized volume-based procurement in a public hospital from the perspective of value-based healthcare[J]. China Pharmacy, 2021, 32(19): 2410-2414.] DOI: 10.6039/j.issn.1001-0408.2021.19.18.

33.张金玲, 陈辉. 药品集中带量采购对我院降压药使用情况的影响[J]. 湖北科技学院学报（医学版）, 2023, 37(2): 145-150. [Zhang JL, Chen H. The effect of the centralized drug procurement on the anti-hypertensive drugs used in our hospital[J]. Journal of Hubei University of Science and Technology (Medical Sciences), 2023, 37(2): 145-150.] DOI: 10.16751/j.cnki.2095-4646.2023.02.0145.

34.Qu J, Zuo W, Took R L, et al. A nationwide survey exploring physicians' and pharmacists' knowledge, awareness and perceptions regarding generic medicines in China[J]. BMC Health Serv Res, 2022, 22: 1069. DOI: 10.1186/s12913-022-08438-9.

35.闫伟, 周颖玉, 刘云涛, 等. 中国居民对仿制药的认知及其相关因素的调查和分析[J]. 中国医院药学杂志, 2022, 42(18): 1943-1947. [Yan W, Zhou YY, Liu YT, et al. Analysis of chinese residents'cognition of generic drugs and its related factors[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(18): 1943-1947.] DOI: 10.13286/j.1001-5213.2022.18.17.

36.谢金平, 张雪瑞, 张赫, 等. 国家药品集中采购政策的主要利益相关者分析[J]. 中国药房, 2021, 32(21): 2677-2682. [Xie JP, Zhang XR, Zhang H, et al. Analysis of key stakeholders in the national drug centralized procurement policy[J]. China Pharmacy, 2021, 32(21): 2677-2682.] DOI: 10.6039/j.issn.1001-0408.2021.21.20.

37.柏林, 王婷, 范平安, 等. 关于不同国家医生对仿制药认知和态度的分析[J]. 中国医院药学杂志, 2020, 40(5): 474-480. [Bo  L, Wang T, Fan PA, et al. Analysis of perceptions and attitudes of physicians regarding generic drugs in different countries[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(5): 474-480.] DOI: 10.13286/j.1001-5213.2020.05.02.

38.王淼, 王旭涛, 李玉莹, 等. 一致性评价对中国仿制药行业的影响[J]. 中国医药工业杂志, 2024, 55(11): 1583-1588. [Wang  M, Wang XT, Li YY, et al. Impact of consistency evaluation on the generic drug industry in china[J]. Chinese Journal of Pharmaceuticals, 2024, 55(11): 1583-1588.] DOI: 10.16522/j.cnki.cjph.2024.11.017.